{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:13:27Z","timestamp":1770966807236,"version":"3.50.1"},"reference-count":27,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":4276,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933800259889_abs1\" sec-type=\"other\"><jats:title>Objective<\/jats:title><jats:p>To evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (SOC).<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800259889_abs2\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>This open-label, 26-week, multi-centre, randomised study compared aripiprazole with SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. The outcome research variables included the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), and the EuroQoL-5D (EQ-5D). The results from these outcome research variables are the focus of this paper addressing quality of life and patient preference.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800259889_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>A total of 555 patients were randomised to receive aripiprazole (<jats:italic>n<\/jats:italic> = 284) or SOC (<jats:italic>n<\/jats:italic> = 271). The OC data at Week 26, reported that more respondents rated the study medication as \u2018much better\u2019 compared with their previous medication in the aripiprazole group versus SOC for patients (59% vs 35%, <jats:italic>P<\/jats:italic> &lt; 0.001) and caregivers (58% vs 30%, <jats:italic>P<\/jats:italic> = 0.014). The improvement in QLS total score was also significantly greater in the aripiprazole group compared with SOC \u2013 mean change from baseline in QLS total score of 16.21 vs 10.01 (<jats:italic>P<\/jats:italic> &lt; 0.001) at Week 26 (OC data set). A greater proportion of patients (93% vs 85%; <jats:italic>P<\/jats:italic> = 0.005) in the aripiprazole group had a satisfactory response on the EQ-5D Self Care Scale; all other EQ-5D scores were similar.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800259889_abs4\" sec-type=\"conclusions\"><jats:title>Conclusion<\/jats:title><jats:p>The study findings suggest that quality of life and patient medication preference measures were better for aripiprazole than for SOC.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2008.03.006","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T13:28:30Z","timestamp":1208611710000},"page":"336-343","source":"Crossref","is-referenced-by-count":13,"title":["Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: Results from the STAR study"],"prefix":"10.1017","volume":"23","author":[{"given":"David","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Loze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Pans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"L'Italien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800259889_bib9","first-page":"1079","volume":"63","author":"Jones","year":"2006","journal-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry"},{"key":"S0924933800259889_bib7","first-page":"220","volume":"111","author":"Haro","year":"2005","journal-title":"Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study Acta Psychiatr Scand"},{"key":"S0924933800259889_bib5","first-page":"199","volume":"16","year":"1990","journal-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life Health Policy"},{"key":"S0924933800259889_bib4","first-page":"1095","volume":"35","author":"Dolan","year":"1997","journal-title":"Modelling valuations for EQ-5D health states Medical Care"},{"key":"S0924933800259889_bib10","first-page":"3","volume":"162","author":"Karow","year":"2002","journal-title":"Subjective well-being and quality of life under atypical antipsychotic treatment Psychopharmacology (Berl)"},{"key":"S0924933800259889_bib3","first-page":"131","volume":"8","author":"de Millas","year":"2006","journal-title":"The impact of subjective well-being under neuroleptic treatment on compliance and remission Dialogues Clin Neurosci"},{"key":"S0924933800259889_bib17","first-page":"12","volume":"68","author":"Mitchell","year":"2007","journal-title":"Adherence behaviour with psychotropic medication is a form of self-medication Med Hypotheses"},{"key":"S0924933800259889_bib1","first-page":"877","volume":"18","author":"Awad","year":"2004","journal-title":"Impact of atypical antipsychotics on quality of life in patients with schizophrenia CNS Drugs"},{"key":"S0924933800259889_bib26","first-page":"201","volume":"57","author":"Voruganti","year":"2002","journal-title":"Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study Schizophr Res"},{"key":"S0924933800259889_bib20","first-page":"24","volume":"107","author":"Prieto","year":"2003","journal-title":"A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study Acta Psychiatr Scand Suppl"},{"key":"S0924933800259889_bib14","first-page":"1209","volume":"353","author":"Lieberman","year":"2005","journal-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med"},{"key":"S0924933800259889_bib2","first-page":"6","author":"Corey-Lisle","year":"2004","journal-title":"Aripiprazole vs haloperidol in acute mania: health-related quality of life (HRQoL). Abstract and poster presented at the 56th Institute on Psychiatric Services, Atlanta, GA, USA, October"},{"key":"S0924933800259889_bib21","first-page":"827","volume":"20","author":"Prieto","year":"2004","journal-title":"Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients Curr Med Res Opin"},{"key":"S0924933800259889_bib6","first-page":"692","volume":"161","author":"Gilmer","year":"2004","journal-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia Am J Psychiatry"},{"key":"S0924933800259889_bib8","first-page":"388","volume":"10","author":"Heinrichs","year":"1984","journal-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome Schizophr Bull"},{"key":"S0924933800259889_bib11","first-page":"433","volume":"22","author":"Kerwin","year":"2007","journal-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients: Schizophrenia Trial of Aripiprazole (STAR) study Eur Psychiatry"},{"key":"S0924933800259889_bib12","first-page":"330","volume":"33","author":"Konnopka","year":"2006","journal-title":"Discriminative ability, construct validity and sensitivity to change of the EQ-5D quality of life questionnaire in paranoid schizophrenia Psychiatr Prax"},{"key":"S0924933800259889_bib16","first-page":"20","author":"L'Italien","year":"2006","journal-title":"Metabolic effects of aripiprazole versus Standard of Care (The STAR Trial). American Psychiatric Association 159th Annual Meeting, Toronto, Canada, May"},{"key":"S0924933800259889_bib13","first-page":"5","volume":"18","author":"Lambert","year":"2004","journal-title":"Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life CNS Drugs"},{"key":"S0924933800259889_bib15","first-page":"106","volume":"18","author":"Lindstrom","year":"2000","journal-title":"Patient compliance with drug therapy in schizophrenia: economic and clinical issues Pharmacoeconomics"},{"key":"S0924933800259889_bib18","first-page":"57","volume":"20","author":"Nasrallah","year":"2006","journal-title":"Improving patient outcomes in schizophrenia: achieving remission J Psychopharmacol"},{"key":"S0924933800259889_bib19","volume-title":"Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia","year":"2002"},{"key":"S0924933800259889_bib22","first-page":"128","volume":"31","author":"Roick","year":"2004","journal-title":"Quality of life instruments and health state preferences to assess effects of medical interventions for mentally and medically ill patients Psychiatr Prax"},{"key":"S0924933800259889_bib23","first-page":"329","volume":"11","author":"Sebastian","year":"2004","journal-title":"Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia Curr Med Chem"},{"key":"S0924933800259889_bib25","first-page":"77","volume":"84","author":"Tandon","year":"2006","journal-title":"A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) Schizophr Res"},{"key":"S0924933800259889_bib27","first-page":"2313","volume":"23","author":"Wolf","year":"2007","journal-title":"A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA) Curr Med Res Opin"},{"key":"S0924933800259889_bib24","first-page":"428","volume":"164","author":"Swartz","year":"2007","journal-title":"Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study Am J Psychiatry"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933808015150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933808015150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800259889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T09:29:04Z","timestamp":1587115744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800259889\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0924933800259889"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2008.03.006","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}